Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance
Drug Resistance Updates · 2026-03 · 85 · 101350
DOI: 10.1016/j.drup.2026.101350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Lenka Trnkova und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, Bratisl…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, DNA Methylation, Paclitaxel, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French National Research Agency, Horizon 2020 Societal Challenges, Horizon 2020.
Themen: Onkologische Pflege
Abstract (Originalsprache)
AIMS: Chemotherapy resistance remains a major challenge in breast cancer (BC) treatment. This study aimed to investigate the role of DNA methylation in this complex process and evaluate the potential of the DNA methyltransferase inhibitor decitabine (DAC) in restoring chemosensitivity. METHODS: Paclitaxel (PAC)- and doxorubicin (DOX)- resistant BC cell lines were derived from luminal A (T-47D), triple-negative (MDA-MB-231), and HER2-positive (JIMT-1) models and characterized by molecular profiling and functional assays. The therapeutic effects of DAC and DOX were assessed in MDA-MB-231 xenografts, and integrative analyses of DNA methylation and gene expression identified pathways associated with resistance. Follow-up analyses were performed in PAC-resistant MAS98.12 patient-derived xenografts (PDX) and in clinical samples from the NeoAva trial (NCT00773695). RESULTS: Resistant cells exhibited a slow-cycling phenotype, reduced tumorigenicity, and widespread genomic alterations. PAC-resistant xenografts showed extensive methylation and transcriptomic reprogramming, partly restored by DAC, which increased Ki-67 expression and enhanced DOX responsiveness. In contrast, PDX tumors displayed less pronounced changes, predominantly hypomethylation, indicating distinct resistance mechanisms. Importantly, xenograft-derived CpG signatures stratified NeoAva patients by treatment response. CONCLUSIONS: Chemoresistance in BC involves extensive genomic and epigenetic remodeling. Although DAC can modulate methylation and tumor phenotype, rational drug combinations will be required to overcome resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, Slovakia. Electronic address: lenka.trnkova@savba.sk.
- Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, Slovakia. Electronic address: monika.burikova@savba.sk.
- Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia; Department of Human Genetics, Institute for Clinical and Translational Research, Biomedical Research…
- Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia. Electronic address: andrej.ficek@uniba.sk.
- Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, Slovakia. Electronic address: jana.plava@savba.sk.
- Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska cesta 9, Bratislava, Slovakia. Electronic address: andrea.cumova@savba.sk.
Förderung
- French National Research Agency
- Horizon 2020 Societal Challenges
- Horizon 2020
- Horizon 2020 Framework Programme
- Vedecká grantová agentúra MŠVVaŠ SR a SAV
- European Regional Development Fund
Zitieren
APA
Trnkova, L., Burikova, M., Soltysova, A., Ficek, A., Plava, J., Cumova, A., Rojikova, L., Jakic, K., Sedlackova, E., Tichy, B., Bystry, V., Busato, F., Shen, Y., Matuskova, M., Kucerova, L., Øy, G. F., Mælandsmo, G. M., Fleischer, T., Tost, J., …, & Smolkova, B. (2026). Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance. Drug Resistance Updates, 85, 101350. https://doi.org/10.1016/j.drup.2026.101350
Vancouver
Trnkova L, Burikova M, Soltysova A, Ficek A, Plava J, Cumova A, et al. Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance. Drug Resistance Updates. 2026;85:101350. doi:10.1016/j.drup.2026.101350
BibTeX
@article{Trnkova2026,
author = {Trnkova, Lenka and Burikova, Monika and Soltysova, Andrea and Ficek, Andrej and Plava, Jana and Cumova, Andrea and Rojikova, Lucia and Jakic, Kristina and Sedlackova, Eva and Tichy, Boris and Bystry, Vojtech and Busato, Florence and Shen, Yimin and Matuskova, Miroslava and Kucerova, Lucia and Øy, Geir Frode and Mælandsmo, Gunhild Mari and Fleischer, Thomas and Tost, Jorg and Miklikova, Svetlana and Cihova, Marina and Buocikova, Verona and Smolkova, Bozena},
title = {Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance},
journal = {Drug Resistance Updates},
year = {2026},
volume = {85},
pages = {101350},
doi = {10.1016/j.drup.2026.101350}
}
EUVIMED